Volume 3, Issue 1
Editorialp. 1
Parkinsons disease vaccine: clinical trial challenges when striving for disease modification
Author(s): Achim Schneeberger, Alexandra Kutzelnigg,Markus Mandler
Editorialp. 9
What the new US FDA guidance in assessing suicidal ideation and behavior in clinical trials means for trial design
Author(s): David W Morris
News and Viewsp. 13-16
New treatment option for delivering anticancer drugs demonstrated in clinical trial
Interviewp. 17
European Society for Medical Oncology 2012 annual meeting: update on oncology trials
Author(s): Christoph Zielinski
Research Updatep. 21
Identifying and prioritizing unmet research questions for people with tinnitus: the James Lind Alliance Tinnitus Priority Setting Partnership
Author(s): Deborah A Hall,Najibah Mohamad, Lester Firkins, Mark Fenton, David Stockdale(on behalf of the Steering Group)
Methodologyp. 29
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Author(s): Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Clinical Trail Prospectivep. 37
Randomization in clinical trials: can we eliminate bias?
Author(s): Oleksandr Sverdlov,William F Rosenberger
Clinical Trail Methodologyp. 49
Clinical trials in pediatric multiple sclerosis: overcoming the challenges
Author(s): Sunita Venkateswaran, Brenda Banwell
Clinical Trail Methodologyp. 57
Rethinking Phase II clinical trial design in heart failure
Author(s): Kory J Lavine , Douglas L Mann
Review: Clinical Trail Outcomesp. 69
New advances in the diagnosis and treatment of pediatric tuberculosis
Author(s): Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomesp. 83
Targeted therapy for hepatocellular carcinoma: current status and future direction
Author(s): Stephen L Chan, Tony Mok
Acknowledgementsp. 95
